cas 2448173-19-9|| where to buy 4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

Название продукции:4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

IUPAC Name:4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

: CAS：2448173-19-9; Молекулярная формула：C10H11IN4O; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)	Количество

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2448173-19-9 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:2448173-19-9; Молекулярная формула:C10H11IN4O; Точка плавления:-; Smiles-код:IC1=CC2=C(N=CN=C2N1)N1CCOCC1; Плотность:

: Номер в каталоге:CM1045040; Молекулярная масса:330.13; Точка кипения:; Номер Mdl:; Хранение:

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: BMF-219; Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.